Soleno Therapeutics Inc (SLNO) reported a strong performance for Q3 2025, with earnings per share (EPS) of $0.47, significantly surpassing Wall Street's expectations of $0.05. Revenue reached $0.1 billion, exceeding the anticipated $0.0 billion.
The company's EPS of $0.47 marked an impressive $0.42 above the consensus estimate. This update provides insight into Soleno's operational performance and financial health, reflecting stronger-than-anticipated business fundamentals.
The firm, headquartered in Redwood City, California, operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases. Its lead product candidate, diazoxide choline extended-release tablets (DCCR), targets Prader-Willi syndrome (PWS) in individuals aged four years and older, addressing critical needs in this patient population.
Soleno Therapeutics will host its earnings conference call after market close to discuss these results and provide additional insights. Investors are encouraged to review the full earnings release and listen to management's commentary for a comprehensive understanding of the quarter's performance and future outlook.
Upcoming earnings are scheduled for February 24, 2026, with an estimated EPS of $0.4423 and revenue of $0.1 billion, followed by another report on May 4, 2026, projecting an EPS of $0.5905.
This brief was generated from structured financial data and reviewed by the Investing Point editorial team. It is for informational purposes only and does not constitute investment advice.